Valeant Pharmaceuticals is reaching out to potential buyers for its specialty contact lens manufacturing division, Paragon Vision Sciences, amid scrutiny from the Federal Trade Commission, according to two people familiar with the matter.
A sale of Paragon, which Valeant’s Bausch & Lomb unit purchased earlier this year for an undisclosed sum, would deal a blow to the specialty pharmaceutical company’s attempt to consolidate the market for gas permeable contact lenses, a type of rigid lens popular among people with keratoconus, a thinning disorder of the cornea, among other eye diseases.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
The FTC has been investigating Valeant for potentially cornering a portion of the lens market…
Read the full story at Reuters, BY CARL O’DONNELL
READ MORE: Michael Pearson
From 2010, Valeant shares rose more than 10-fold to peak in August. Unfortunately, from a systemic perspective, just about every American is worse off as a result of Valeant’s strategy. Still, Valeant More…
Valeant Issues Statement On Sales Of Company Stock as follow: Valeant Pharmaceuticals International, Inc. stated that 1, 297, 399 shares pledged to Goldman Sachs to secure loans made to chairman and chief More…
Teva likely mean the end of Teva’s pursuit of another Teva Pharmaceutical Industries Ltd. likely mean the end of pursuit of Mylan acquisition. The Israeli world’s biggest generic pharmaceutical maker is More…
The seven-month battle over American Botox haven pharmaceutical company Allergan is over, after it accepted a friendly takeover bid from Irish integrated specialty pharmaceutical Actavis. The Actavis offer of combined More…
Last week pharmaceuticals company Allergan Inc, the Irvine California based maker of Botox received a second, increased, takeover offer from Quebec based Valeant Pharmaceuticals. The Valeant bid More…
